Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH135629FSA
  • |
  • Pages: 50
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Supernus Pharmaceuticals Inc (SUPN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Supernus Pharmaceuticals Inc (Supernus) is a specialty pharmaceutical company which develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; and Trokendi XR (topiramate), an initial monotherapy against partial onset or primary generalized tonic-clonic seizures and an adjunct therapy for the treatment of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome. Its technology platforms include Microtrol (multiparticulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company operates through its subsidiary Supernus Europe Ltd. Supernus is headquartered in Rockville, Maryland, the US.

Supernus Pharmaceuticals Inc Key Recent Developments

Feb 28,2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results

Nov 14,2016: Supernus Provides Business Update

Aug 12,2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman

Aug 02,2016: Supernus Announced Second Quarter 2016 Financial Results

Aug 02,2016: Supernus Announces Second Quarter 2016 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

Supernus Pharmaceuticals Inc-Key Facts 6

Supernus Pharmaceuticals Inc-Key Employees 7

Supernus Pharmaceuticals Inc-Key Employee Biographies 8

Supernus Pharmaceuticals Inc-Major Products and Services 9

Supernus Pharmaceuticals Inc-Pharmaceutical Pipeline Products Data 10

Supernus Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Supernus Pharmaceuticals Inc, Pipeline Products by Development Phase 10

Supernus Pharmaceuticals Inc-History 12

Supernus Pharmaceuticals Inc-Company Statement 14

Supernus Pharmaceuticals Inc-Locations And Subsidiaries 15

Head Office 15

Other Locations & Subsidiaries 15

Section 2-Company Analysis 16

Supernus Pharmaceuticals Inc-Business Description 16

Supernus Pharmaceuticals Inc-Corporate Strategy 17

Supernus Pharmaceuticals Inc-SWOT Analysis 18

SWOT Analysis-Overview 18

Supernus Pharmaceuticals Inc-Strengths 18

Supernus Pharmaceuticals Inc-Weaknesses 19

Supernus Pharmaceuticals Inc-Opportunities 20

Supernus Pharmaceuticals Inc-Threats 21

Supernus Pharmaceuticals Inc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Supernus Pharmaceuticals Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Feb 28, 2017: Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results 32

Nov 14, 2016: Supernus Provides Business Update 34

Aug 12, 2016: Supernus Announces Resignation of Dr. James Barrett from Board of Directors; Charles W. Newhall, III Elected Chairman 36

Aug 02, 2016: Supernus Announced Second Quarter 2016 Financial Results 37

Aug 02, 2016: Supernus Announces Second Quarter 2016 Financial Results 39

May 03, 2016: Supernus Announces First Quarter 2016 Financial Results 41

Apr 01, 2016: Supernus Pharmaceuticals Selects DSG for EDC and IWRS in Phase 3 Clinical Studies on Impulsive Aggression in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder 43

Mar 02, 2016: Supernus Announces Record Fourth Quarter and Full Year 2015 Financial Results 44

Section 6-Appendix 46

Methodology 46

Ratio Definitions 46

About GlobalData 50

Contact Us 50

Disclaimer 50

List of Figures

Supernus Pharmaceuticals Inc, Pipeline Products by Therapy Area 10

Supernus Pharmaceuticals Inc, Pipeline Products by Development Phase 10

Supernus Pharmaceuticals Inc, Performance Chart (2012-2016) 26

Supernus Pharmaceuticals Inc, Ratio Charts 28

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 30

List of Tables

Supernus Pharmaceuticals Inc, Key Facts 6

Supernus Pharmaceuticals Inc, Key Employees 7

Supernus Pharmaceuticals Inc, Key Employee Biographies 8

Supernus Pharmaceuticals Inc, Major Products and Services 9

Supernus Pharmaceuticals Inc, Number of Pipeline Products by Development Stage 11

Supernus Pharmaceuticals Inc, History 12

Supernus Pharmaceuticals Inc, Subsidiaries 15

Supernus Pharmaceuticals Inc, Key Competitors 22

Supernus Pharmaceuticals Inc, Ratios based on current share price 23

Supernus Pharmaceuticals Inc 24

Supernus Pharmaceuticals Inc (Cont...1) 25

Supernus Pharmaceuticals Inc, Interim Ratios 27

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 29

Supernus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 30

Supernus Pharmaceuticals Inc, Recent Deals Summary 31

Currency Codes 46

Capital Market Ratios 46

Equity Ratios 47

Profitability Ratios 47

Cost Ratios 48

Liquidity Ratios 48

Leverage Ratios 49

Efficiency Ratios 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Sunovion Pharmaceuticals Inc Shire Plc Neurovance Inc Neos Therapeutics Inc Desitin Arzneimittel GmbH Alcobra Ltd

Supernus Pharmaceuticals Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts

select a license

Single User License
USD 125 INR 8431
Site License
USD 250 INR 16863
Corporate User License
USD 375 INR 25294

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com